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Abstract
Objectives This systematic review aimed to assess the role
of magnetic resonance imaging (MRI) in evaluating residual
disease extent and the ability to detect pathologic complete
response (pCR) after neoadjuvant chemotherapy for inva-
sive breast cancer.
Methods PubMed, the Cochrane Library, MEDLINE, and
Embase databases were searched for relevant studies pub-
lished until 1 July 2012. After primary selection, two
reviewers independently assessed the content of each eligi-
ble study using a standardised extraction form and pre-
defined inclusion and exclusion criteria.
Results A total of 35 eligible studies were selected. Corre-
lation coefficients of residual tumour size assessed by MRI
and pathology were good, with a median value of 0.698.
Reported sensitivity, specificity, positive predictive value and
negative predictive value for predicting pCRwithMRI ranged
from 25 to 100 %, 50–97 %, 47–73 % and 71–100 %, respec-
tively. Both overestimation and underestimation were ob-
served. MRI proved more accurate in determining residual
disease than physical examination, mammography and ultra-
sound. Diagnostic accuracy of MRI after neoadjuvant chemo-
therapy could be influenced by treatment regimen and breast
cancer subtype.
Conclusions Breast MRI accuracy for assessing residual
disease after neoadjuvant chemotherapy is good and sur-
passes other diagnostic means. However, both overestima-
tion and underestimation of residual disease extent could be
observed.
Main Messages
• Breast MRI accuracy for assessing residual disease is
good and surpasses other diagnostic means.
• Correlation coefficients of residual tumour size assessed
by MRI and pathology were considered good.
• However, both overestimation and underestimation of
residual disease were observed.
• Diagnostic accuracy of MRI seems to be affected by
treatment regimen and breast cancer subtype.
Keywords Breast cancer . MRI . Neoadjuvant
chemotherapy . Residual disease
Introduction
Neoadjuvant chemotherapy (NAC) is defined as the admin-
istration of chemotherapy to treat invasive breast cancer
before local treatment (i.e. surgery). Although in breast
cancer patients NAC was primarily used for treatment of
locally advanced disease stages, its use has been extended to
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the treatment of early stage breast cancers in order to enable
breast-conserving therapy for patients who would otherwise
undergo mastectomy. In a large meta-analysis by Mauri et
al., no significant differences in survival or overall disease
progression was observed between patients receiving adjuvant
or neoadjuvant chemotherapy [1].
Some physicians prefer NAC instead of the adjuvant
chemotherapy because of the ability to assess tumour re-
sponse in vivo. In this situation, reliable assessment of
pathological tumour response to NAC is vital in order to
select the most appropriate surgical plan. An imaging mo-
dality that could assess tumour response to NAC would be
beneficial, providing it could detect any residual disease
present. This could result in a surgical treatment plan more
tailored to the individual patient. In addition, pathological
complete response (pCR, i.e. the absence of any residual
invasive tumour cells) on NAC has shown to be a prognostic
factor for overall better survival, disease-free survival
and recurrence-free survival [2]. In the future, this latter
information might also guide further adjuvant treatment
recommendations.
Many examinations have been proposed to evaluate re-
sidual disease and/or complete response to therapy (such as
clinical examination, mammography and ultrasound), but
their accuracy was only of modest degree [3]. Parallel to
these findings, (contrast-enhanced) magnetic resonance im-
aging (MRI) of the breast proved to be superior to mam-
mography and ultrasound with respect to assessing tumour
extent, presence of additional foci (i.e. multifocality and/or
multicentricity) and the presence of contralateral breast
tumours [4, 5]. Therefore, MRI might be a promising imag-
ing tool to assess therapy response in the NAC setting and
for assessing pCR.
Several reviews have been recently published that
assessed the ability of breast MRI to predict pCR in patients
receiving NAC [6–8]. However, pCR is only achieved by a
minority of patients and as a consequence, the role of breast
MRI in neoadjuvant chemotherapy was not investigated for
a substantial number of patients that still have some degree
of residual disease after treatment. In this systematic review,
we aimed to address the role of breast MRI in assessing both
residual disease extent and pCR after NAC in breast cancer
patients. Our study purpose was to assess the role of mag-
netic resonance imaging (MRI) in the evaluation in all
patients receiving neoadjuvant chemotherapy for invasive
breast cancer.
Materials and methods
For this systematic review, Embase, the Cochrane library,
MEDLINE and citations as provided by PubMed were
searched until 1 July 2012, using the search terms breast,
breast neoplasms, breast neoplasm, breast cancer, breast
carcinoma and breast lesion combined with the search terms
magnetic resonance imaging, MRI, MR mammography and
neoadjuvant therapy, neoadjuvant chemotherapy, neoadju-
vant systemic therapy, neoadjuvant, chemotherapy, primary
therapy and initial therapy. Only original articles were con-
sidered for inclusion (i.e. no reviews, brief communications
or letters to the editor). References of all retrieved articles
were manually searched for additional relevant manuscripts.
Studies found through these search terms were assessed for
potential eligibility by reading the abstracts first and then
applying inclusion and exclusion criteria.
Included were only those in which breast MRI was per-
formed at baseline and prior to surgery (but after completion
of neoadjuvant chemotherapy). In addition, the ability of
MRI to assess pCR was one of our study aims. Rates of pCR
to NAC may vary, depending on the treatment regime used:
6–15 % in antracycline-based therapies, up to 30 % when
adding taxanes [9]. Therefore, in order to have some reliable
information on the ability of MRI to assess residual disease
and also pCR, eligible studies should have a sufficiently
large study population. To be eligible for this review, we
decided that a study should consist of at least 25
patients (in the final analysis) with newly diagnosed,
histologically proven breast cancer undergoing neoadjuvant
chemotherapy who were imaged using clinical MRI scanners
(i.e. minimum 1.5 T).
Studies were not excluded if other imaging modalities
were performed parallel to MRI in order to evaluate treatment
response.
After this initial assessment, the publications were sum-
marised separately by two radiologists using a standard
extraction form. When discrepancies were encountered,
consensus opinion was reached afterwards. Extracted data
included: first author, year of publication, study design
(retrospective or prospective), blinding procedures, popula-
tion size, mean patient age and range, magnetic field
strength, contrast agent/dose used, breast cancer stage at
inclusion, tumour histology, breast cancer subtypes, chemo-
therapy regimen, imaging response assessment [World
Health Organisation (WHO) criteria, Response Evaluation
Criteria in Solid Tumours (RECIST) criteria or other] and
histopathological response assessment.
While scoring the extraction forms in consensus, some
studies were excluded if the study outcome proved not to
contain information on residual disease evaluation by MRI.
All reported P-values ≤0.05 were considered statistically
significant. The large heterogeneity observed in the in-
cluded studies precluded us from pooling data (see also
‘Discussion’ section), which is why we chose to use de-
scriptive statistics in this review. Since this was a systematic
review, no approval from our institutional review board was
necessary.
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Results
In the primary literature search, 3,119 potential studies were
identified, of which 515 were double in various searches,
leaving 2,604 studies after the primary search. After reading
the abstracts, 2,444 were excluded from further evaluation,
leaving 160 studies to be analysed using the inclusion and
exclusion criteria. In these studies, two additional studies
were identified by manually searching the references in the
manuscripts. In this analysis, another 98 studies did not
comply with our eligibility criteria and were subsequently
excluded, leaving 64 studies to be reviewed using the ex-
traction form and consensus reading. This led to the exclu-
sion of another 29 studies, because they did not address the
topic of residual disease assessment with MRI after neo-
adjuvant chemotherapy. Therefore, a total of 35 studies were
eligible for this systematic review [10–45]. Figure 1
presents a more detailed overview of the study selection
process.
The majority of studies (27) were prospective in design.
A total of 2,359 patients were included in the studies (mean
65.5 patients per study, range 30–216). Median age of
patients was 48.0 years (range 23–82 years). Three studies
were performed on a 3-T MRI scanner, four on both 1.5- and
3-T scanners, and the remaining studies on 1.5-T MRI
scanners. In all studies, a commercially available
gadolinium-based contrast agent was used for breast MRI
at regular clinical administration doses. Interestingly, there
was a remarkable heterogeneity in breast cancer stages and
subtypes, neoadjuvant chemotherapy regimens, and meth-
ods used for assessing response in both imaging and
histopathological analyses (Tables 1 and 2). This heteroge-
neity precluded us from further pooling of data in a meta-
analysis.
Seventeen studies calculated correlation coefficients for
the comparison of MRI tumour measurements compared
with histopathological results [13, 14, 17, 21, 22, 25, 27,
28, 31–35, 37, 39, 40, 43]. Correlation coefficients varied
from poor to excellent, but the median value was 0.698
(range 0.21–0.982, Table 3). Nonetheless, two studies
reported non-significant correlation coefficients. In the rel-
atively small (n=59) retrospective study by Guarneri et al.,
the correlation coefficients were similar for MRI (0.53) and
ultrasound (0.66) when compared to histopathology, and
both were non-significant [35]. In the study of 86 women
by Nakahara et al., the correlation coefficient of all included
patients was remarkably low (0.21), but rose to a strikingly
high and statistically significant value of 0.92 when only
triple-negative breast cancer types were analysed [31]. A
weak correlation coefficient (0.30) was also presented by
Chen et al. However, when four cases with a size discrep-
ancy larger than 5 cm were excluded (all HER2-negative
tumours presenting as non-mass-like enhancement), the cor-
relation coefficient increased remarkably to 0.76 (P<0.001)
[39]. Furthermore, both overestimation and underestimation
were observed by multiple studies [10, 13, 15, 16, 20, 22,
24, 32, 37].
Although correlation coefficients are useful tools to de-
scribe MRI’s ability to assess response to NAC, it could
mask the truth, since the same trend in all studies could
result in excellent correlation between histopathological
results and MRI measurements, yet the actual estimation
Pubmed: 1478 initial studies
Embase 1602 initial studies
The Cochrane Library: 39 initial studies 
Total: 3119 separate studies (515 doubles)
First selection based on the abstracts 
2444 excluded: 1435 other clinical domain
918 other goal
47 other index test
44 not available 
160 eligible studies
During the second selection the in- and exclusion criteria were applied on the entire study
98 excluded: 26 review articles 
16 other goal
2 other index test
54 not complied with the in- and exclusion 
criteria
+2 included: 2 additional studies identified by searching 
the references manually
64 studies potentially eligible for systematic review 
35 included in final analysis (i.e. assessment of residual disease as study outcome)
Fig. 1 Detailed overview of
study selection
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Table 1 Overview of included studies
















2001 Prospective 33 46 (32–75) IIIa, IIIb, IIIc, to
large for breast
conserving therapy
IDC, ILC, inflammatory ER, PR






2002 Prospective 52 47 (29–72) Not reported Not reported Not reported
Cheung et al. 2003 Prospective 33 45 (29–63) Not reported IDC, ILC, mucinous
carcinoma
Not reported
Denis et al. 2004 Prospective 40 48 (29–64) LABC Not reported Not reported
Warren et al. 2004 Retrospective 67 46 (28–62) Not reported Not reported ER, PR
Martincich
et al.
2004 Prospective 30 49 (36–65) II, III, inoperable
locally-advanced
breast cancer
IDC, ILC ER, PR
















Segara et al. 2007 Prospective 68 50 (29–71) Clinical stage I, II,
and III
IDC, ILC, mixed ductal
and lobular carcinoma;
sometimes DCIS or
LCIS present in lesions
ER, PR, HER2
Kim et al. 2007 Prospective 50 42 (25–68) IIb, IIIa, IIIb, IIIc IDC, ILC ER, PR
Chen et al. 2007 Prospective 51 50 (31–77) II, III, IV IDC, ILC HER2
Bhattacharyya
et al.
2008 Prospective 32 42 (24–60) >4 cm, large tumours
in small breasts,
node involvement
Not reported Not reported
Moon et al. 2009 Prospective 195 46 (not reported) Not reported Not reported ER, PR, HER2






























Wang et al. 2010 Prospective 43 48 (34–69) II, III IDC Not reported
Dongfeng
et al.







2011 Prospective 31 51 (37–72) Not reported IDC, ILC ER, PR, HER2
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of pCR might not be accurate. Therefore, the variation of
size evaluation between MRI and pathology yields addition-
al information. Bhattacharyya et al. reported an overestima-
tion of >10 mm in 4 of 32 cases [24]. Belli et al. described a
mean overestimation and underestimation of 2.1 and
2.0 mm, respectively [20]. These numbers were 20.2 and
13.8 mm in the study by Denis et al. [15]. Partridge et al.
found the smallest deviation with an overestimation of MRI
measurements of only 0.9 mm [13]. The studies by Guarneri
et al. and Lyou et al. found a mean size difference of 1.6 and
6.0 mm, respectively [35, 38].
With respect to pCR prediction with MRI, sensitivity was
considered to be the proportion of patients with pCR that were
correctly classified with MRI as complete responders. Speci-
ficity was considered to be the proportion of patients with
non-pCR correctly classified by MRI as non-responders. To
illustrate, a sensitivity of 62% in these studies meant that in 62
out of 100 patients, MRI was able to correctly identify patients
with pCR (i.e. MRI did not show any residual enhancement).
Eight studies calculated the diagnostic accuracies for MRI in
predicting pCR (Table 4) [12, 18, 24, 25, 29, 34, 43, 45]. Two
studies reported diagnostic accuracies for diffusion-weighted
MR imaging, and both reported a sensitivity of 100 % [43,
45]. Specificity was 70% and 91%. Only one study evaluated
the potential of MR spectroscopy parameters (total choline-
containing compounds, tCho) and reported a sensitivity of
53 % and a specificity of 70 % [43]. The remaining studies
used dynamic, contrast-enhanced MR imaging. Median (and
range) sensitivity and specificity were 42 % (25–92 %) and
89 % (50–97 %), respectively. If reported, median (and range)
PPV and NPV were 64 % (50–73 %) and 87 % (71–96 %),
respectively.
Interestingly, only three studies compared diagnostic ac-
curacy of MRI and ultrasound for assessing residual disease
[19, 21, 25]. In these studies, ultrasound was less accurate
than MRI. MRI was also more accurate than mammography
in assessing residual disease, but only one study performed
this comparison [19]. Finally, MRI was more accurate than
physical examination for assessing residual disease, which
was examined by three studies [19, 21, 44].
Table 1 (continued)






Breast cancer types Breast cancer
subtypes
Guarneri et al. 2011 Retrospective 59 48 (30–70) IIa, IIb, IIIa, IIIb, IIIc IDC, ILC, other n.o.s. ER, PR, HER2
Loo et al. 2011 Prospective 118 46 (23–76) >3 cm IDC, ILC, adenocarcinoma
n.o.s.
ER, HER2
Shin et al. 2011 Prospective 43 43 (25–62) LABC/inflammatory
breast cancer and







Lyou et al. 2011 Retrospective 57 44 (24–64) Not reported IDC, ILC Not reported















Takeda et al. 2012 Prospective 37 51 (30–78) Not reported Not reported Not reported







Hylton et al. 2012 Prospective 216 48 (26–68) T3 tumour of









Overview of included studies regarding year of publication, study design, size of study population, age of population, breast cancer stages of
patients included, breast cancer types observed in the respective studies and their subtypes
LABC locally advanced breast cancer, BCT breast-conserving therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal
carcinoma in situ, n.o.s. not otherwise specified, ER estrogen receptor, PR progesterone receptor, and HER human epidermal growth factor receptor
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Discussion
In this systematic review, we aimed to analyse the available
data on MRI accuracy for assessing residual disease and
pCR after neoadjuvant chemotherapy in breast cancer
patients.
Many studies compared the measured tumour diameter or
volumes on MRI with pathological results as the gold stan-
dard. Correlation coefficients for these comparisons were
good to excellent, but both overestimation and underestima-
tion of the MRI size measurements were frequently ob-
served. Although these correlation coefficients were good,
it does not necessarily mean that agreement between these
measurements is good. The majority of studies did not
investigate the agreement between these measurements, for
instance by using Bland-Altman plots [46].
Contrast-enhanced breast MRI is superior to other imag-
ing modalities to assess breast tumour extent and the pres-
ence of multicentricity or multifocality [4, 5]. However,
overestimation of tumour extent is a well-known phenome-
non in (preoperative) breast MRI [47, 48] and was also
observed in the NAC setting. Confounding factors in over-
estimating tumour size might be: reactive inflammation
caused by tumour response and healing, surrounding scle-
rosis and necrosis, multiple scattered lesions and presence of
accompanying ductal carcinoma in situ [19, 20, 22]. In
theory, overestimation of tumour size by MRI could result
in an altered surgical treatment plan for the individual pa-
tient, with the risk of achieving wider resection margins
(with poorer cosmetic results) or performing unnecessary
mastectomy (where breast-conserving therapy would have
been possible).
In contrast to overestimation of tumour size by MRI,
underestimation was also observed in the NAC setting.
Causes might be antivascular effects of docetaxel (resulting
in less tumour enhancement), lack of inflammatory response
surrounding the tumour in docetaxel patients, more exten-
sive ductal carcinoma in situ components and partial volume
effects in very small foci of residual disease [13, 15, 21].
Underestimation of residual disease could lead to positive
resection margins with viable residual tumour cells, necessi-
tating re-surgery. In addition, positive resection margins are
associated with an increased long-term risk of disease recur-
rence in patients who have undergone breast-conserving ther-
apy [49]. Straver et al. attempted to create an MRI-based
model that could help in surgical decision making. In this
study, MRI underestimated tumour size >20 mm in 17 % of
the patients, in 13 % leading to an incorrect decision to
perform breast-conserving surgery. From their study, they
Table 3 Correlation coefficients of MRI and histopathological tumour
measurements
Author Correlation coefficient P-value
Partridge et al. 0.89 <0.001
Cheung et al. 0.982 <0.001
Martincich et al. 0.72 <0.001
Segara et al. 0.749 <0.0001
Kim et al. 0.645 <0.001
Moon et al. 0.584 NA
Wright et al. 0.49 NA
Park et al. 0.667 NA
Nakahara et al. 0.21 NS
Wang et al. 0.866 <0.01
Dongfeng et al. 0.698 <0.001
Fangberget et al. 0.87 <0.001
Guarneri et al. 0.53 NS
Shin et al.a 0.97 NA
Chen et al. 0.30 0.03
Kim et al. 0.619 <0.0001
Shin et al.b 0.781 NA
NA not available, NS not significant
a 2011 paper, b 2012 paper
Table 4 Diagnostic accuracies
of MRI for predicting pathologic
complete response
PPV positive predictive value,
NPV negative predictive value,
NA not available, tCho total
choline-containing compounds
The results are presented for
dynamic, contrast-enhanced
MRI, with the exception of:
adiffusion-weighted imaging and
bMR spectroscopy parameters
Author Sensitivity (%) Specificity (%) PPV (% NPV (%) Accuracy (%) Prevalence
Rieber et al. 42 89 73 71 72 0.21
Schott et al. 25 97 50 94 89 0.10
Bhattacharyya
et al.
80 89 56 96 NA 0.13
Moon et al. 38 96 NA NA NA 0.15
De Los Santos
et al.
92 50 72 80 NA 0.40
Fangberget
et al.
38 96 NA NA NA 0.37
Park et al. 100a 70a 47a 100a 77a 0.21
Shin et al. 77 70 NA NA NA 0.33
100a 91a NAa NAa NAa
53b 70b NAb NAb NAb
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concluded that baseline tumour size, tumour size reduction
and cancer subtype should be taken into account in the optimal
selection of patients eligible for breast-conserving therapy
[30].
Seven studies provided an overview of the diagnostic
accuracy of MRI to predict pCR. Median sensitivity and
specificity were 42 % and 89 %, respectively. If reported,
median PPVand NPV were 64 % and 87 %, respectively. In
a meta-analysis of 25 studies, Yuan et al. showed that pooled
weighted estimates of sensitivity and specificity of MRI for
demonstrating pCR were 63 % (range 56–70 %) and 91 %
(range 89–92 %) [6]. These findings were concordant with
the observations made by Wu et al., who performed a meta-
analysis of 34 studies [7]. They concluded that the sensitiv-
ity and specificity of contrast-enhanced breast MRI to pre-
dict pCR were 68 % and 91 %, respectively. These values
are slightly discrepant with the observations of our current
review. The variation in these findings, especially in speci-
ficity, might be explained by the differences in included
studies, since these recent publications additionally included
studies with smaller populations and lower MRI field
strengths. Since pCR is only achieved in up to 30 % of
patients, we think that a minimum number of ten patients is
too low to accurately use pCR as a study outcome. There-
fore, we chose a minimum number of 25 patients to be
included in our final analysis. Despite the differences in
these reviews and our current study, the diagnostic accuracy
of breast MRI to predict pCR seems to have a high speci-
ficity and NPV versus only moderate sensitivity and PPV.
Nevertheless, the varying results in the separate studies (and
their range) of the recent reviews show that MRI's accuracy
for assessing pCR is still under debate and that it is too early
to use it as a decision-making tool in studies that investigate
other treatment strategies after pCR besides surgery.
Although the number of studies was small, contrast-
enhanced MRI outperformed physical examination, ultra-
sound and mammography in accurately assessing residual
disease. In physical examination, this is most likely
explained by fibrosis surrounding the tumour bed as a result
of the therapy. This fibrotic tissue remains hard, and as such
it could lead to misinterpretation of residual disease. These
fibrotic changes can also be observed in mammography and
ultrasound and cannot be easily discerned from residual
tumour tissue, but can be excluded by MRI since this
fibrotic tissue does not show any enhancement after contrast
administration. In addition, the diagnostic accuracy of mam-
mography is strongly dependent on breast density, being
lower in breasts with extremely dense fibroglandular tissue
[50]. If performed in the right period of the menstrual cycle
(day 3–14 in premenopausal women), the accuracy of breast
MRI was less influenced by breast density [51].
Almost all papers used contrast-enhanced breast MRI for
the evaluation of residual disease and pCR after NAC. Some
studies additionally investigated the ability of diffusion-
weighted imaging (DWI) for assessing pCR after NAC. In
DWI, MRI is used to assess the Brownian motions of water
molecules within a certain tissue of interest. In the cell-rich
environment of tumours, the motion of these molecules is
restricted and can be measured with DWI. This results in
increased signal intensity on so-called diffusion-weigted
images, with corresponding low values for the apparent-
diffusion coefficient or ADC. Woodhams et al. demonstrat-
ed that the sensitivity, specificity and accuracy of DWI for
assessing pCR was higher than contrast-enhanced breast
MRI, but the differences observed were not significant with
p-values of 0.31, 0.08 and 0.06, respectively [26]. In the
study by Park et al., DWI was compared to positron emis-
sion computed tomography (PET-CT) and showed a slightly
higher AUC for predicting pCR when compared to PET-CT,
although this difference was not statistically significant in
their population of 34 patients, of which 7 achieved pCR
after therapy [45]. In the study by Shin et al., three different
MRI techniques were compared: dynamic contrast-enhanced
MRI, DWI and MR spectroscopy. They concluded that the
change in ADC after treatment was the most accurate predic-
tor of pCR. With an AUC of 0.96, they found that the optimal
cutoff value for percentage ADC change was 40.7 %, yielding
a sensitivity of 100 % and a specificity of 91 % [43].
This review has some important limitations. First, publi-
cation bias is a study limitation that merits attention in each
systematic review. Small studies with less favorable results
tend to be published less frequently or not at all. With this
potential bias in mind, one should realise that the current
positive findings of MRI accuracy after NAC might be
overestimated.
Second, the lack of study uniformity prevented us from
performing a meta-analysis. Therefore, we chose to perform
a systematic review of the selected studies and provide a
descriptive presentation of the observed findings instead of
performing a meta-analysis that uses statistical models to
adjust for this heterogeneity to some extent. Variations in
study aim, chemotherapy regimens, response assessment
criteria in both imaging and pathological analysis, patient
populations and breast cancer subtypes precluded us from
drawing more definitive conclusions. For example, Chen et
al. showed in their study that MRI can predict pCR accu-
rately in HER2-positive patients, but a high false-negative
rate was observed in HER2-negative patients, especially
when they received anti-angiogenic drugs [23]. Loo et al.
showed in their study of 118 patients that response moni-
toring after NAC is effective in triple-negative or HER2-
positive breast cancer subtypes, but is inaccurate in ER-
positive/HER2-negative subtypes [36]. In their 2011 publi-
cation, Chen et al. demonstrated that MR imaging accuracy
was higher for HER2-positive cancer types than for HER2-
negative tumours (88 % versus 82 %). In the same study,
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they showed that the average size discrepancy in cases with
Ki-67 staining of <10 % was greater than in cases with Ki-67
staining of >40 % [39]. But also the choice of chemothera-
peutic regimen can influence MRI accuracy. Denis et al.
showed that MRI frequently underestimated residual tumour
size in taxane-containing treatments, most likely because of
the antivascular effects of these drugs, resulting in less en-
hancement on contrast-enhanced MRI [15].
Third, the method of evaluating treatment response in
imaging and pathology is important. Although no significant
differences between WHO and RECIST criteria in imaging
response assessment were observed in other cancer types,
multiple response criteria were used in the selected studies
[52, 53]. Similarly, there are no widely accepted response
assessment criteria for pathology. The most important issue
in this assessment is the extent of residual DCIS. Whether or
not DCIS is included in the analysis might partly explain the
differences observed inMRI over- and underestimation. From
a clinical point of view, it would be most interesting to assess
MRI accuracy if DCIS were included in the definition of pCR,
since DCIS should also be excised during surgery and identi-
fication of DCIS extension by MRI remains challenging [54].
Fourth, the population size of the majority of studies is
relatively small. Only four studies had a population size
>100 subjects [25, 30, 36, 44] and most of the studies were
single-centre studies. The statistical noise will be smaller if
the sample sizes are increased in (future) multicentre studies
in order to assess the true accuracy of MRI in the NAC
setting with greater confidence.
In summary, breast MRI accuracy for assessing resid-
ual disease after neoadjuvant chemotherapy is good, but
multiple factors, such as cancer subtype and treatment
regimen, can influence MRI accuracy and should be
considered in clinical decision making. Both overesti-
mation and underestimation can be observed and might
have important clinical impact. Clinical decision making
based on MRI results should therefore be made prudent-
ly with these limitations in mind. Regardless of the
many potential confounders described in this review,
we feel that assessment of NAC response with MRI is
promising and ready for more multicentre studies that
are able to address these shortcomings.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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